<prompt> Please answer with one of the option in the bracket. Write reasoning in between . Write answer in between .Q:A 49-year-old man presents with an 11-month history of progressive fatigue. He denies any night sweats, weight loss, abdominal pain, nausea, vomiting, change in bowel habits, or bleeding. He has no significant past medical history. His vital signs include: temperature 37.0C 98.6F, blood pressure 11981 mm Hg, pulse 83min, and respiratory rate 19min. On physical examination, mild splenomegaly is noted on abdominal percussion. Laboratory findings are significant for a leukocyte count of 16,700mm3 and a low serum leukocyte alkaline phosphatase LAP score. A bone marrow biopsy is performed, which shows marked hypercellularity with a clear dominance of granulocytes. Cytogenetic analysis is positive for the Ph1 gene. Which of the following is the best course of treatment for this patient?? A: Hydroxyurea, B: Interferon-α-2b, C: Rituximab, D: Cytarabine, E: Imatinib,  <response>: Based on the patients symptoms of fatigue, splenomegaly, high leukocyte count, low LAP score, and bone marrow biopsy findings showing granulocyte hyperplasia, this patient most likely has chronic myeloid leukemia CML. The presence of the Ph1 gene on cytogenetics confirms the diagnosis of CML. The treatment options listed include:A Hydroxyurea - A chemotherapy drug that inhibits DNA synthesis. Used in CML to help control high white blood cell counts.B Interferon-α-2b - Immunotherapy drug with anti-proliferative effects. Can be used to treat early stage CML. C Rituximab - Monoclonal antibody against CD20 on B cells. Used in B cell lymphomas, not indicated in CML.D Cytarabine - Chemotherapy drug, antimetabolite. Used in acute leukemias like AML, not first line for CML. E Imatinib - Tyrosine kinase inhibitor that targets the BCR-ABL fusion protein. First line treatment for chronic phase CML.E: Imatinib 